Celularity Inc. Share Price

CELU

US1511902041

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 07/10/2026 BST			5-day change	1st Jan Change
1.470 ^USD	-6.96%		+8.89%	+32.43%

09-24	Celularity Inc. Announces Appointment of Philip A. Barach to Board	CI
08-27	Celularity Inc. And MuseCell Innovations Pte. Ltd. Announce U.S. Manufacturing Collaboration For The Dezawa MuseCell Platform	CI

Analysts' recommendations: Celularity Inc.

30/01/23	HC Wainwright Lowers Price Target on Celularity to $2.50 From $15, Maintains Buy Rating	MT
30/01/23	Morgan Stanley Downgrades Celularity to Underweight From Equalweight, Adjusts Price Target to $1 From $5	MT
22/12/22	Oppenheimer Downgrades Celularity to Perform From Outperform, Removes $6 Price Target	MT
14/11/22	Oppenheimer Adjusts Celularity Price Target to $6 From $8, Maintains Outperform Rating	MT
12/09/22	Morgan Stanley Trims Celularity's Price Target to $5 From $8, Keeps Equalweight Rating	MT

More recommendations

Press Releases: Celularity Inc.

09-30	Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner	AQ
09-29	Celularity : Quarterly Report for Quarter Ending March 31, 2026 (Form 10-Q)	PU
09-29	Celularity Announces Naveen Jain to Join Board of Directors	AQ
09-24	Celularity Announces Over $10 Million Initial Financing Closing as Part of Up to $28 Million Recapitalization to Accelerate Growth Following Significant Operating Improvements	AQ
08-27	Celularity and MuseCell Innovations® Announce U.S. Manufacturing Collaboration for the Dezawa MuseCell® Platform	BU

More press releases

News in other languages: Celularity Inc.

07/08/24	Cellectis : nomination d'un nouveau directeur médical
07/08/24	Cellectis : nomination d'un nouveau directeur médical
13/01/23	Celularity et CH Trading Group annoncent la conclusion d'un accord de distribution de produits avec Tamer Group qui sera leur distributeur exclusif en Arabie Saoudite
13/01/23	Celularity et CH Trading Group annoncent un accord de distribution territoriale au Moyen-Orient
05/12/22	Robert J. Hariri, M.D., Ph.D., PDG de Celularity, discute « l’utilisation de la science et de la technologie pour prolonger la longévité humaine en bonne santé » à la conférence FII

More news

Managers and Directors: Celularity Inc.

Manager	Title	Age	Since
Robert Hariri Gordon CEO	Chief Executive Officer	66	31/12/2015
John Sprague DFI	Director of Finance/CFO	67	26/02/2026
K Fletcher CMP	Compliance Officer	42	30/06/2021

Director	Title	Age	Since
Robert Hariri Gordon CHM	Chairman	66	31/12/2015
Peter Diamandis BRD	Director/Board Member	64	30/06/2017
Steven Gordon BRD	Director/Board Member	58	18/06/2026

More insiders

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. Its IMPACT manufacturing platform is a fully integrated process designed to optimize the speed of the sourcing of placentas from full-term healthy informed consent donors through the use of proprietary processing methods, cell selection, product-specific chemistry, manufacturing and control (CMC), advanced cell manufacturing and cryopreservation. It also provides contract manufacturing and development services to third parties.

Employees

115

Sector

Pharmaceuticals

More about the company

Quotes

Date	Price	Change	Volume
07/10/26	US$1.470	-6.96%	68,828
06/10/26	US$1.580	-7.60%	260,947
05/10/26	US$1.710	+6.87%	282,127
02/10/26	US$1.600	+15.94%	221,844
01/10/26	US$1.380	+2.22%	142,148

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Celularity Inc.

Company calendar

Market Cap	51.27M 45.81M 42.74M 38.82M 73.11M 4.96B 73.66M 514M 201M 2.52B 192M 188M 8.11B	P/E 2024	-0.79x	P/E 2025	-0.31x
Enterprise Value	120M 107M 99.87M 90.72M 171M 11.59B 172M 1.2B 469M 5.89B 450M 440M 18.95B	EV / Sales 2024	2.12x	EV / Sales 2025	3.77x
Free-Float	66.83%	Yield 2024 *	-	Yield 2025	-

09-24	Celularity Inc. Announces Appointment of Philip A. Barach to Board	CI
08-27	Celularity Inc. And MuseCell Innovations Pte. Ltd. Announce U.S. Manufacturing Collaboration For The Dezawa MuseCell Platform	CI
08-20	NexGel Files to Register 15.25 Million Shares From Note Conversions	MT
08-07	Celularity Inc Announces Termination of Rick Gonzalez from Chief Commercial Officer, Effective August 5, 2026	CI
06-30	Celularity Inc. Announces Resignation of Vincent LeVien as Director, Effective June 26, 2026	CI
06-30	Celularity Inc. Enters into a Loan Agreement with the Philip & Daniele Barach Family Trust	CI
06-26	Celularity Appoints Chief Operating Officer	MT
06-25	Celularity Inc Announces Executive and Board Appointments	CI
06-04	Celularity Inc. and Fountain Life Management, LLC Announces Availability Of Cenplacel-L For Investigational Use Under New Florida LA	CI
06-02	Celularity Inc. Appoints Rick Gonzalez as Chief Commercial Officer, Effective May 29, 2026	CI
05-28	Celularity - enters settlement agreement with Helena on May 21, 2026	RE
05-01	Celularity Regains Nasdaq Listing Compliance, Shares Rise	MT
04-30	Celularity Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI

1 day	-6.96%
1 week	+8.89%
Current month	+8.89%
1 month	-4.55%
3 months	+102.28%
6 months	+5.76%
Current year	+32.43%

1 week	1.3	1.8
1 month	1.13	1.8
Current year	0.56	2.55
1 year	0.56	2.55
3 years	0.56	7.97
5 years	0.56	131.86
10 years	0.56	134

Date	Insider	Type	Main position	Quantity	% Market Cap.
23/09/26	Philip A Barach	Others		6,425,301	26.8288%
23/09/26	Philip A Barach	Others	Director	6,425,301	26.8288%
23/09/26	Philip A Barach	Others		6,425,301	26.8288%

Celularity Inc. Share Price

Stocks

CELU

US1511902041

Pharmaceuticals

Valuation: Celularity Inc.

Chart: Celularity Inc.

Latest news: Celularity Inc.

Analysts' recommendations: Celularity Inc.

Press Releases: Celularity Inc.

News in other languages: Celularity Inc.

Quotes and Performance

Price Extremes

Managers and Directors: Celularity Inc.

Latest insider transactions

Biopharmaceuticals

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CELULARITY INC.	-6.96%	+8.89%	-	-	51.27M
Average	-6.96%
Weighted average by Cap.	-6.96%

	2024	2025
Net sales	54.22M 48.45M 45.2M 41.05M 77.32M 5.24B 77.9M 543M 212M 2.67B 204M 199M 8.58B	26.55M 23.72M 22.13M 20.1M 37.86M 2.57B 38.14M 266M 104M 1.31B 99.67M 97.52M 4.2B
Net income	-57.89M -51.73M -48.26M -43.83M -82.56M -5.6B -83.17M -580M -227M -2.85B -217M -213M -9.16B	-91.72M -81.95M -76.46M -69.45M -131M -8.87B -132M -919M -359M -4.51B -344M -337M -14.51B
Net Debt	68.1M 60.85M 56.77M 51.56M 97.11M 6.59B 97.84M 682M 267M 3.35B 256M 250M 10.77B	68.54M 61.24M 57.13M 51.9M 97.74M 6.63B 98.47M 687M 268M 3.37B 257M 252M 10.84B

Markets		Quality
Nasdaq	CELU	Delayed
CBOE	CELU	Real-time